StreetInsider.com News Articles http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 05 Mar 2026 08:20:00 +0000 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI http://www.streetinsider.com/Press+Releases/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html <p>DENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that it has completed the required enrollment in the SAVE Registry, a Post-Approval Study (PAS) required by the FDA that is designed to confirm the safety of the QUELIMMUNE™ therapy as a treatment for children with acute kidney injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT). The registry has successfully enrolled 50 patients, and the company will be reporting the 28-day safety results from the SAVE Registry to the FDA upon completion of http://www.streetinsider.com/Press+Releases/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html Thu, 05 Mar 2026 08:20:00 +0000 A.06822034 A.16030647 A.50216646 ICU O.20026344 O.34978779 O.46997375 O.49532464 SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI http://www.streetinsider.com/Press+Releases/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html <p>DENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that it has completed the required enrollment in the SAVE Registry, a Post-Approval Study (PAS) required by the FDA that is designed to confirm the safety of the QUELIMMUNE™ therapy as a treatment for children with acute kidney injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT). The registry has successfully enrolled 50 patients, and the company will be reporting the 28-day safety results from the SAVE Registry to the FDA upon completion of http://www.streetinsider.com/Press+Releases/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html Thu, 05 Mar 2026 08:20:00 +0000 A.06822034 A.16030647 A.50216646 ICU O.20026344 O.34978779 O.46997375 O.49532464 SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI http://www.streetinsider.com/Press+Releases/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html <p>DENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that it has completed the required enrollment in the SAVE Registry, a Post-Approval Study (PAS) required by the FDA that is designed to confirm the safety of the QUELIMMUNE™ therapy as a treatment for children with acute kidney injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT). The registry has successfully enrolled 50 patients, and the company will be reporting the 28-day safety results from the SAVE Registry to the FDA upon completion of http://www.streetinsider.com/Press+Releases/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html Thu, 05 Mar 2026 08:20:00 +0000 A.06822034 A.16030647 A.50216646 ICU O.20026344 O.34978779 O.46997375 O.49532464 SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI http://www.streetinsider.com/Press+Releases/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html <p>DENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that it has completed the required enrollment in the SAVE Registry, a Post-Approval Study (PAS) required by the FDA that is designed to confirm the safety of the QUELIMMUNE™ therapy as a treatment for children with acute kidney injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT). The registry has successfully enrolled 50 patients, and the company will be reporting the 28-day safety results from the SAVE Registry to the FDA upon completion of http://www.streetinsider.com/Press+Releases/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html Thu, 05 Mar 2026 08:20:00 +0000 A.06822034 A.16030647 A.50216646 ICU O.20026344 O.34978779 O.46997375 O.49532464 SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI http://www.streetinsider.com/Press+Releases/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html <p>DENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that it has completed the required enrollment in the SAVE Registry, a Post-Approval Study (PAS) required by the FDA that is designed to confirm the safety of the QUELIMMUNE™ therapy as a treatment for children with acute kidney injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT). The registry has successfully enrolled 50 patients, and the company will be reporting the 28-day safety results from the SAVE Registry to the FDA upon completion of http://www.streetinsider.com/Press+Releases/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html Thu, 05 Mar 2026 08:20:00 +0000 A.06822034 A.16030647 A.50216646 ICU O.20026344 O.34978779 O.46997375 O.49532464 SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI http://www.streetinsider.com/Press+Releases/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html <p>DENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that it has completed the required enrollment in the SAVE Registry, a Post-Approval Study (PAS) required by the FDA that is designed to confirm the safety of the QUELIMMUNE™ therapy as a treatment for children with acute kidney injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT). The registry has successfully enrolled 50 patients, and the company will be reporting the 28-day safety results from the SAVE Registry to the FDA upon completion of http://www.streetinsider.com/Press+Releases/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html Thu, 05 Mar 2026 08:20:00 +0000 A.06822034 A.16030647 A.50216646 ICU O.20026344 O.34978779 O.46997375 O.49532464 SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI http://www.streetinsider.com/Press+Releases/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html <p>DENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that it has completed the required enrollment in the SAVE Registry, a Post-Approval Study (PAS) required by the FDA that is designed to confirm the safety of the QUELIMMUNE™ therapy as a treatment for children with acute kidney injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT). The registry has successfully enrolled 50 patients, and the company will be reporting the 28-day safety results from the SAVE Registry to the FDA upon completion of http://www.streetinsider.com/Press+Releases/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html Thu, 05 Mar 2026 08:20:00 +0000 A.06822034 A.16030647 A.50216646 ICU O.20026344 O.34978779 O.46997375 O.49532464 SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI http://www.streetinsider.com/Press+Releases/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html <p>DENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that it has completed the required enrollment in the SAVE Registry, a Post-Approval Study (PAS) required by the FDA that is designed to confirm the safety of the QUELIMMUNE™ therapy as a treatment for children with acute kidney injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT). The registry has successfully enrolled 50 patients, and the company will be reporting the 28-day safety results from the SAVE Registry to the FDA upon completion of http://www.streetinsider.com/Press+Releases/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html Thu, 05 Mar 2026 08:20:00 +0000 A.06822034 A.16030647 A.50216646 ICU O.20026344 O.34978779 O.46997375 O.49532464 SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI http://www.streetinsider.com/Globe+Newswire/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html <p>DENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that it has completed the required enrollment in the SAVE Registry, a Post-Approval Study (PAS) required by the FDA that is designed to confirm the safety of the QUELIMMUNE™ therapy as a treatment for children with acute kidney injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT). The registry has successfully enrolled 50 patients, and the company will be reporting the 28-day safety results from the SAVE Registry to the FDA upon completion of http://www.streetinsider.com/Globe+Newswire/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html Thu, 05 Mar 2026 08:20:00 +0000 A.06822034 A.16030647 A.50216646 ICU O.20026344 O.34978779 O.46997375 O.49532464 SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI http://www.streetinsider.com/Globe+Newswire/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html <p>DENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that it has completed the required enrollment in the SAVE Registry, a Post-Approval Study (PAS) required by the FDA that is designed to confirm the safety of the QUELIMMUNE™ therapy as a treatment for children with acute kidney injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT). The registry has successfully enrolled 50 patients, and the company will be reporting the 28-day safety results from the SAVE Registry to the FDA upon completion of http://www.streetinsider.com/Globe+Newswire/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html Thu, 05 Mar 2026 08:20:00 +0000 A.06822034 A.16030647 A.50216646 ICU O.20026344 O.34978779 O.46997375 O.49532464 SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI http://www.streetinsider.com/Globe+Newswire/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html <p>DENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that it has completed the required enrollment in the SAVE Registry, a Post-Approval Study (PAS) required by the FDA that is designed to confirm the safety of the QUELIMMUNE™ therapy as a treatment for children with acute kidney injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT). The registry has successfully enrolled 50 patients, and the company will be reporting the 28-day safety results from the SAVE Registry to the FDA upon completion of http://www.streetinsider.com/Globe+Newswire/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html Thu, 05 Mar 2026 08:20:00 +0000 A.06822034 A.16030647 A.50216646 ICU O.20026344 O.34978779 O.46997375 O.49532464 SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI http://www.streetinsider.com/Globe+Newswire/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html <p>DENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that it has completed the required enrollment in the SAVE Registry, a Post-Approval Study (PAS) required by the FDA that is designed to confirm the safety of the QUELIMMUNE™ therapy as a treatment for children with acute kidney injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT). The registry has successfully enrolled 50 patients, and the company will be reporting the 28-day safety results from the SAVE Registry to the FDA upon completion of http://www.streetinsider.com/Globe+Newswire/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html Thu, 05 Mar 2026 08:20:00 +0000 A.06822034 A.16030647 A.50216646 ICU O.20026344 O.34978779 O.46997375 O.49532464 SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI http://www.streetinsider.com/Globe+Newswire/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html <p>DENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that it has completed the required enrollment in the SAVE Registry, a Post-Approval Study (PAS) required by the FDA that is designed to confirm the safety of the QUELIMMUNE™ therapy as a treatment for children with acute kidney injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT). The registry has successfully enrolled 50 patients, and the company will be reporting the 28-day safety results from the SAVE Registry to the FDA upon completion of http://www.streetinsider.com/Globe+Newswire/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html Thu, 05 Mar 2026 08:20:00 +0000 A.06822034 A.16030647 A.50216646 ICU O.20026344 O.34978779 O.46997375 O.49532464 SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI http://www.streetinsider.com/Globe+Newswire/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html <p>DENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that it has completed the required enrollment in the SAVE Registry, a Post-Approval Study (PAS) required by the FDA that is designed to confirm the safety of the QUELIMMUNE™ therapy as a treatment for children with acute kidney injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT). The registry has successfully enrolled 50 patients, and the company will be reporting the 28-day safety results from the SAVE Registry to the FDA upon completion of http://www.streetinsider.com/Globe+Newswire/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html Thu, 05 Mar 2026 08:20:00 +0000 A.06822034 A.16030647 A.50216646 ICU O.20026344 O.34978779 O.46997375 O.49532464 SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI http://www.streetinsider.com/Globe+Newswire/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html <p>DENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that it has completed the required enrollment in the SAVE Registry, a Post-Approval Study (PAS) required by the FDA that is designed to confirm the safety of the QUELIMMUNE™ therapy as a treatment for children with acute kidney injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT). The registry has successfully enrolled 50 patients, and the company will be reporting the 28-day safety results from the SAVE Registry to the FDA upon completion of http://www.streetinsider.com/Globe+Newswire/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html Thu, 05 Mar 2026 08:20:00 +0000 A.06822034 A.16030647 A.50216646 ICU O.20026344 O.34978779 O.46997375 O.49532464 SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI http://www.streetinsider.com/Globe+Newswire/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html <p>DENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that it has completed the required enrollment in the SAVE Registry, a Post-Approval Study (PAS) required by the FDA that is designed to confirm the safety of the QUELIMMUNE™ therapy as a treatment for children with acute kidney injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT). The registry has successfully enrolled 50 patients, and the company will be reporting the 28-day safety results from the SAVE Registry to the FDA upon completion of http://www.streetinsider.com/Globe+Newswire/SeaStar+Medical+Announces+Completion+of+FDA+Enrollment+Requirement+for+SAVE+Surveillance+Registry+Evaluating+QUELIMMUNE+Safety+for+Pediatric+AKI/26115587.html Thu, 05 Mar 2026 08:20:00 +0000 A.06822034 A.16030647 A.50216646 ICU O.20026344 O.34978779 O.46997375 O.49532464 Form SCHEDULE 13G/A SeaStar Medical Holding Filed by: INTRACOASTAL CAPITAL, LLC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++SeaStar+Medical+Holding++++++++++++++++Filed+by%3A+INTRACOASTAL+CAPITAL%2C+LLC/26001396.html si-local-file:///var/storage/secattach/20260213/26001396.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++SeaStar+Medical+Holding++++++++++++++++Filed+by%3A+INTRACOASTAL+CAPITAL%2C+LLC/26001396.html Fri, 13 Feb 2026 16:44:00 +0000 ICU O.49532464 Form SCHEDULE 13G/A SeaStar Medical Holding Filed by: INTRACOASTAL CAPITAL, LLC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++SeaStar+Medical+Holding++++++++++++++++Filed+by%3A+INTRACOASTAL+CAPITAL%2C+LLC/26001396.html si-local-file:///var/storage/secattach/20260213/26001396.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++SeaStar+Medical+Holding++++++++++++++++Filed+by%3A+INTRACOASTAL+CAPITAL%2C+LLC/26001396.html Fri, 13 Feb 2026 16:44:00 +0000 ICU O.49532464 SeaStar Medical Holding Corp. (ICU) PT Lowered to $6 at Maxim Group http://www.streetinsider.com/Analyst+PT+Change/SeaStar+Medical+Holding+Corp.+%28ICU%29+PT+Lowered+to+%246+at+Maxim+Group/25983008.html <p>Maxim Group analyst Anthony Vendetti lowered the price target on SeaStar Medical Holding Corp. (NASDAQ: ICU) to $6.00 while maintaining a Buy rating.</p> http://www.streetinsider.com/Analyst+PT+Change/SeaStar+Medical+Holding+Corp.+%28ICU%29+PT+Lowered+to+%246+at+Maxim+Group/25983008.html Wed, 11 Feb 2026 15:57:30 +0000 ICU Form 4 SeaStar Medical Holding For: Feb 06 Filed by: Van Heel Kenneth http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SeaStar+Medical+Holding+++For%3A+Feb+06++Filed+by%3A+Van+Heel+Kenneth/25976780.html si-local-file:///var/storage/secattach/20260210/25976780.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SeaStar+Medical+Holding+++For%3A+Feb+06++Filed+by%3A+Van+Heel+Kenneth/25976780.html Tue, 10 Feb 2026 16:59:00 +0000 ICU O.49532464 Form 4 SeaStar Medical Holding For: Feb 06 Filed by: Van Heel Kenneth http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SeaStar+Medical+Holding+++For%3A+Feb+06++Filed+by%3A+Van+Heel+Kenneth/25976780.html si-local-file:///var/storage/secattach/20260210/25976780.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SeaStar+Medical+Holding+++For%3A+Feb+06++Filed+by%3A+Van+Heel+Kenneth/25976780.html Tue, 10 Feb 2026 16:59:00 +0000 ICU O.49532464 Form 4 SeaStar Medical Holding For: Feb 06 Filed by: Vincent Bernadette N http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SeaStar+Medical+Holding+++For%3A+Feb+06++Filed+by%3A+Vincent+Bernadette+N/25976766.html si-local-file:///var/storage/secattach/20260210/25976766.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SeaStar+Medical+Holding+++For%3A+Feb+06++Filed+by%3A+Vincent+Bernadette+N/25976766.html Tue, 10 Feb 2026 16:58:00 +0000 ICU O.49532464 Form 4 SeaStar Medical Holding For: Feb 06 Filed by: Vincent Bernadette N http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SeaStar+Medical+Holding+++For%3A+Feb+06++Filed+by%3A+Vincent+Bernadette+N/25976766.html si-local-file:///var/storage/secattach/20260210/25976766.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SeaStar+Medical+Holding+++For%3A+Feb+06++Filed+by%3A+Vincent+Bernadette+N/25976766.html Tue, 10 Feb 2026 16:58:00 +0000 ICU O.49532464 Form 4 SeaStar Medical Holding For: Feb 06 Filed by: Neuman John http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SeaStar+Medical+Holding+++For%3A+Feb+06++Filed+by%3A+Neuman+John/25976775.html si-local-file:///var/storage/secattach/20260210/25976775.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SeaStar+Medical+Holding+++For%3A+Feb+06++Filed+by%3A+Neuman+John/25976775.html Tue, 10 Feb 2026 16:58:00 +0000 ICU O.49532464 Form 4 SeaStar Medical Holding For: Feb 06 Filed by: Neuman John http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SeaStar+Medical+Holding+++For%3A+Feb+06++Filed+by%3A+Neuman+John/25976775.html si-local-file:///var/storage/secattach/20260210/25976775.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SeaStar+Medical+Holding+++For%3A+Feb+06++Filed+by%3A+Neuman+John/25976775.html Tue, 10 Feb 2026 16:58:00 +0000 ICU O.49532464